Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study

Michael R. Grunwald, David J. Kuter, Ivy Altomare, John M. Burke, Aaron T. Gerds, Mark A. Walshauser, Michael R. Savona, Brady Stein, Stephen T. Oh, Philomena Colucci, Shreekant Parasuraman, Dilan Paranagama, Ruben Mesa

Research output: Contribution to journalArticle

Abstract

Background: Polycythemia vera (PV) is associated with increased blood cell counts, risk of thrombosis, and symptoms including fatigue and pruritus. National guidelines support the use of hydroxyurea (HU) in high-risk patients or those with some other clinical indication for cytoreduction. Patients and Methods: REVEAL is a prospective, observational study designed to collect data pertaining to demographics, disease burden, clinical management, patient-reported outcomes, and health care resource utilization of patients with PV in the United States. In this analysis, HU treatment patterns and outcomes were assessed from 6 months prior to enrollment to the time of discontinuation, death, or data cutoff. Results: Of the 1381 patients who received HU for ≥ 3 months, the median HU exposure was 23.6 months (range, 3.1-38.5 months). The most common maximum daily HU doses were 1000 mg (30.6%) and 500 mg (30.1%); only 6.4% received ≥ 2 g/d HU. Approximately one-third (32.3%) of patients had dose adjustments, 23.8% had dose interruptions, and 257 (18.6%) discontinued HU. The most common reasons for HU discontinuations and interruptions were adverse events/intolerance (37.1% and 54.5%, respectively) and lack of efficacy (35.5% and 22.1%, respectively). Of those who received HU for ≥ 3 months, 57.1% had hematocrit values > 45% on ≥ 1 occasion, 33.1% continued to receive phlebotomies, and 27.4% had uncontrolled myeloproliferation. Conclusion: The results of this analysis emphasize the need for active management of patients with PV with appropriate HU dose titration to maintain blood count control while monitoring for signs and symptoms of HU intolerance.

Original languageEnglish (US)
Pages (from-to)219-225
Number of pages7
JournalClinical Lymphoma, Myeloma and Leukemia
Volume20
Issue number4
DOIs
StatePublished - Apr 2020

Keywords

  • Cytopenia
  • Hematocrit
  • Myeloproliferative neoplasm
  • Observational study
  • Prospective

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study'. Together they form a unique fingerprint.

  • Cite this

    Grunwald, M. R., Kuter, D. J., Altomare, I., Burke, J. M., Gerds, A. T., Walshauser, M. A., Savona, M. R., Stein, B., Oh, S. T., Colucci, P., Parasuraman, S., Paranagama, D., & Mesa, R. (2020). Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. Clinical Lymphoma, Myeloma and Leukemia, 20(4), 219-225. https://doi.org/10.1016/j.clml.2019.09.601